Enhanced complement resistance in drug-selected P-glycoprotein expressing multi-drug-resistant ovarian carcinoma cells.
about
Expression of KAP1 in epithelial ovarian cancer and its correlation with drug-resistanceImmunotherapy: a useful strategy to help combat multidrug resistance.Sublytic complement protects prostate cancer cells from tumour necrosis factor-α-induced cell death.lncRNAs are novel biomarkers for differentiating between cisplatin-resistant and cisplatin-sensitive ovarian cancer.
P2860
Enhanced complement resistance in drug-selected P-glycoprotein expressing multi-drug-resistant ovarian carcinoma cells.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Enhanced complement resistance ...... stant ovarian carcinoma cells.
@en
Enhanced complement resistance ...... stant ovarian carcinoma cells.
@nl
type
label
Enhanced complement resistance ...... stant ovarian carcinoma cells.
@en
Enhanced complement resistance ...... stant ovarian carcinoma cells.
@nl
prefLabel
Enhanced complement resistance ...... stant ovarian carcinoma cells.
@en
Enhanced complement resistance ...... stant ovarian carcinoma cells.
@nl
P2093
P2860
P1476
Enhanced complement resistance ...... stant ovarian carcinoma cells.
@en
P2093
K E Odening
M Kirschfink
S Fruehauf
Z Fishelson
P2860
P304
P356
10.1111/J.1365-2249.2008.03817.X
P577
2008-11-24T00:00:00Z